Asunaprevir

摘要

Asunaprevir is a direct-acting antiviral drug for hepatitis C. It works by inhibiting the viral non-structural 3/4A serine protease required for viral replication. Asunaprevir is indicated in combination with daclatasvir for people with compensated liver disease, including cirrhosis. Daclatasvir is also a direct-acting antiviral and works by inhibiting the non-structural 5A protein involved in viral replication. The safety and efficacy of asunaprevir (100 mg twice daily) with daclatasvir (60 mg daily) have been assessed in three main trials (see Table). An open-label study of 643 patients with genotype 1b infection enrolled three types of participants: treatment-naive patients patients who had not responded or only partially responded to previous peginterferon and ribavirin patients intolerant to, and/or ineligible for, peginterferon and ribavirin (this included patients with depression, anaemia, or neutropenia, or compensated advanced fibrosis or cirrhosis with thrombocytopenia).